Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.50
Bid: 36.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 3.00 (8.333%)
Open: 37.50
High: 37.50
Low: 37.50
Prev. Close: 37.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Mr. Mahbubul Alam

9 Jun 2014 07:30

RNS Number : 1316J
Beximco Pharmaceuticals Ltd
09 June 2014
 



 

BEXIMCO PHARMACEUTICALS LTD.

 

 

9th June, 2014

 

 

Mr. Mahbubul Alam

 

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; LSE-AIM: BXP) is sad to announce the death of Mr. Mahbubul Alam who passed away on Friday 6th June, 2014. He had served as a Non-Executive Independent Director of the Company from March 2014. Additionally, he was the Chairman of the Audit Committee.

 

Ahmed Sohail Fasiur Rahman, Chairman of Beximco Pharmaceuticals, said: "The Board of Directors recall with appreciation and gratitude Mr. Mahbubul Alam's contribution towards Beximco Pharmaceuticals Ltd during his short tenure as a Non-Executive Independent Director. The Beximco Pharma Family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at his sad demise."

 

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

 

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

Paul Shackleton

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway/ Victoria Foster-Mitchell

Tel: +44 (0)20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEKLBBZQFZBBV
Date   Source Headline
24th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20212:06 pmRNSSecond Price Monitoring Extn
24th Mar 20212:00 pmRNSPrice Monitoring Extension
24th Mar 202111:06 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
4th Feb 20217:34 amRNSUpdate on the supply of COVID-19 vaccine
28th Jan 20217:00 amRNSHalf Year Results 2020-21
22nd Jan 20217:00 amRNSPayment of Cash Dividend
21st Jan 20219:34 amRNSProposed acquisition of stake in Sanofi Bangladesh
18th Jan 20217:00 amRNSBoard Changes
14th Jan 20219:00 amRNSUpdate on the supply of COVID-19 vaccine
11th Jan 20217:00 amRNSStock Dividend Issued
11th Jan 20217:00 amRNSConfirmation of Board Changes
21st Dec 20207:00 amRNSAGM Statement
2nd Dec 202011:01 amRNSBoard Changes
23rd Nov 20207:00 amRNSNotice of AGM
16th Nov 20207:00 amRNSResults for First Quarter Ended 30 September 2020
13th Nov 20207:00 amRNSResults for First Quarter Ended 30 September 2020
11th Nov 20207:00 amRNSResults for the year ended 30 June 2020
5th Nov 20204:40 pmRNSSecond Price Monitoring Extn
5th Nov 20204:35 pmRNSPrice Monitoring Extension
5th Nov 20202:40 pmRNSMOU with SII and GOB for COVID-19 vaccine
29th Oct 20207:00 amRNSNotification of Preliminary Results and AGM
21st Sep 20207:00 amRNSBeximco Pharma receives eighth FDA approval
28th Aug 202011:06 amRNSSecond Price Monitoring Extn
28th Aug 202011:00 amRNSPrice Monitoring Extension
28th Aug 20208:31 amRNSBeximco and SII to cooperate on a COVID-19 vaccine
30th Jul 20207:00 amRNSBoard Change
23rd Jun 20207:00 amRNSQ3 Financial Results and Business Update
21st May 20207:00 amRNSWorld’s first generic remdesivir for COVID-19
4th May 20207:00 amRNSCOVID-19 Update
30th Mar 20207:00 amRNSBeximco donates PPE to healthcare professionals
24th Feb 20207:00 amRNSBeximco announces Commercial Agreement with Mylan
29th Jan 20207:00 amRNSHalf Year Results 2019-20
20th Jan 202011:06 amRNSPayment of Cash Dividend
23rd Dec 201910:46 amRNSAGM Statement
19th Nov 20198:57 amRNSAGM Notification
14th Nov 20197:00 amRNSResults for First Quarter Ended 30 September 2019
11th Nov 20197:00 amRNSResults for the 12 month period ended 30 June 2019
29th Oct 20197:00 amRNSNotification of Preliminary Results and AGM
8th Aug 20199:18 amRNSUpdate on Dividend and Tax legislation changes
30th Jul 20197:00 amRNSBeximco launches fifth product in the US market
18th Jul 20194:01 pmRNSDividend and Tax changes for Bangladesh companies
29th Apr 20197:00 amRNS3rd Quarter Results
24th Apr 20197:00 amRNSBeximco receives FDA approval for Cyproheptadine
20th Feb 20197:00 amRNSBeximco Pharma to Acquire Eight ANDAs from Sandoz
4th Feb 201911:32 amRNSAppointment of Broker
31st Jan 20197:00 amRNSHalf Year Results 2018-19
22nd Jan 20197:00 amRNSPayment of Cash Dividend
27th Dec 20187:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.